| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Neuropathology*
and
Neurosurgery,
University of Bonn Medical
Center, Bonn; and the Department of
Neuropathology,
Charité, Humboldt
University, Berlin, Germany
Ependymal tumors are heterogeneous with regard to morphology, localization, age at first clinical manifestation, and prognosis. Several molecular alterations have been reported in these tumors, including allelic losses on chromosomes 10, 17, and 22 and mutations in the NF2 gene. However, in contrast to astrocytic gliomas, no consistent molecular alterations have been associated with distinct types of ependymal tumors. To evaluate whether morphological subsets of ependymomas are characterized by specific genetic lesions, we analyzed a series of 62 ependymal tumors, including myxopapillary ependymomas, subependymomas, ependymomas, and anaplastic ependymomas, for allelic losses on chromosome arms 10q and 22q and mutations in the PTEN and NF2 genes. Allelic losses on 10q and 22q were detected in 5 of 56 and 12 of 54 tumors, respectively. Six ependymomas carried somatic NF2 mutations, whereas no mutations were detected in the PTEN gene. All six of the NF2 mutations occurred in ependymomas of WHO grade II and were exclusively observed in tumors with a spinal localization (P = 0.0063). These findings suggest that a considerable fraction of spinal ependymomas are associated with molecular events involving chromosome 22 and that mutations in the NF2 gene may be of primary importance for their genesis. Furthermore, our data suggest that the more favorable clinical course of spinal ependymomas may relate to a distinct pattern of genetic alterations different from that of intracerebral ependymomas.
This article has been cited by other articles:
 |
|
 |
|
  J.-P. Kilday, R. Rahman, S. Dyer, L. Ridley, J. Lowe, B. Coyle, and R. Grundy Pediatric Ependymoma: Biological Perspectives Mol. Cancer Res., June 1, 2009; 7(6): 765 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. de Bont, R. J. Packer, E. M. Michiels, M. L. d. Boer, and R. Pieters Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective Neuro Oncology, December 1, 2008; 10(6): 1040 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mendrzyk, A. Korshunov, A. Benner, G. Toedt, S. Pfister, B. Radlwimmer, and P. Lichter Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin. Cancer Res., April 1, 2006; 12(7): 2070 - 2079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. McClatchey and M. Giovannini Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin Genes & Dev., October 1, 2005; 19(19): 2265 - 2277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V P Collins Brain tumours: classification and genes J. Neurol. Neurosurg. Psychiatry, June 1, 2004; 75(suppl_2): ii2 - ii11. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Korshunov, K. Neben, G. Wrobel, B. Tews, A. Benner, M. Hahn, A. Golanov, and P. Lichter Gene Expression Patterns in Ependymomas Correlate with Tumor Location, Grade, and Patient Age Am. J. Pathol., November 1, 2003; 163(5): 1721 - 1727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Knobbe, A. Merlo, and G. Reifenberger Pten signaling in gliomas Neuro Oncology, July 1, 2002; 4(3): 196 - 211. [Abstract] [PDF]
|
|
|
|
|
|
Y. Hirose, K. Aldape, A. Bollen, C. D. James, D. Brat, K. Lamborn, M. Berger, and B. G. Feuerstein Chromosomal Abnormalities Subdivide Ependymal Tumors into Clinically Relevant Groups Am. J. Pathol., March 1, 2001; 158(3): 1137 - 1143. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
